Sarepta Therapeutics, Inc. SRPT Capitalized Stock Based Compensation And Depreciation As Inventory
Capitalized Stock Based Compensation And Depreciation As Inventory at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept srpt:CapitalizedStockBasedCompensationAndDepreciationAsInventory.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s capitalized stock based compensation and depreciation as inventory.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s capitalized stock based compensation and depreciation as inventory?
- Sarepta Therapeutics, Inc. (SRPT) reported capitalized stock based compensation and depreciation as inventory of $6.93M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s capitalized stock based compensation and depreciation as inventory changed year-over-year?
- Sarepta Therapeutics, Inc.'s capitalized stock based compensation and depreciation as inventory decreased by 4.8% year-over-year, from $7.29M to $6.93M.
- What does capitalized stock based compensation and depreciation as inventory mean?
- Captures the portion of stock-based compensation and depreciation expenses that are allocated to inventory rather than being expensed immediately in the period incurred. This metric highlights the capitalization of production-related overhead costs into asset values. It is essential for understanding how non-cash expenses are deferred and eventually recognized through cost of goods sold.